Efficacy of Oxymetholone in Severe and Nonsevere Acquired Aplastic Anemia: A Propensity Score Matching Analysis.

Published in: Journal of blood medicine (2022)

These results revealed longer survival among the responders of patients with AA, even in the SAA/vSAA group. However, close monitoring of therapeutic responses is still performed. Switching therapy is necessary when remission is undetected after 6 months of oxymetholone treatment.

Keyphrases

chronic kidney disease
early onset
single cell
mesenchymal stem cells
rheumatoid arthritis
combination therapy
systemic lupus erythematosus
free survival
bone marrow
cell therapy